Patents by Inventor Tomoaki Hamada

Tomoaki Hamada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR PRODUCING GLYCAN, BUILDING BLOCK FOR GYLICAN SYNTHESIS, AND COMPOUND
    Publication number: 20230143273
    Abstract: This invention provides a method for producing a glycan with improved yield ratio of streocontrolled glycan. Additionally it provides the building blocks used as the sugar donor and as the sugar acceptor to implement a method for producing the glycan. It also provides a novel compound. It subjects the specific building block A of this invention to electrolytic oxidation in an aprotic organic solvent that contains an electrolyte; and subjects the specific building block B of this invention to glycosylation with the electrolytically oxidized building block A in the method for producing a glycan based on the liquid phase process.
    Type: Application
    Filed: February 25, 2020
    Publication date: May 11, 2023
    Applicants: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, KOGANEI CORPORATION
    Inventors: Toshiki NOKAMI, Toshiyuki ITOH, Hiraku SAKAI, Tomoaki HAMADA
  • CYCLOALKANE-1,3-DIAMINE DERIVATIVE
    Publication number: 20230074669
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
    Type: Application
    Filed: November 24, 2021
    Publication date: March 9, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
  • CYCLOALKANE-1,3-DIAMINE DERIVATIVE
    Publication number: 20230030720
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
    Type: Application
    Filed: December 5, 2019
    Publication date: February 2, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
  • Cycloalkane-1,3-diamine derivative
    Patent number: 11236106
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: February 1, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
  • CYCLOALKANE-1,3-DIAMINE DERIVATIVE
    Publication number: 20210269454
    Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.
    Type: Application
    Filed: April 28, 2021
    Publication date: September 2, 2021
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
  • AMINOPYRAZOLONE DERIVATIVE
    Publication number: 20170107207
    Abstract: The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which has an excellent inhibitory action on the ATPase activity of a TIP48/TIP49 complex and as such, is useful for the treatment of tumors. [Solution] The present invention provides a compound having a structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the present specification.
    Type: Application
    Filed: February 17, 2015
    Publication date: April 20, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Masayuki Ebisawa, Takashi Suzuki, Noriyasu Haginoya, Tomoaki Hamada, Takeshi Murata, Kouichi Uoto, Ryo Murakami, Takehiko Takata